At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the ~70,000 people in the UK living with PKD. Together, the Mironid team each successfully exceeded the 70 km target through […]
Read more de Mironid Raises Awareness for PKD with 1,000 km Team Challenge
ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability continues to limit long-term treatment for a substantial proportion of patients, and both current and emerging approaches target only a single pathway in kidney […]
Our Chief Scientific Officer, Adele Rowley, will be in London on 18 February for this year’s Ace Drug Discovery Summit, where she will be giving a presentation titled “Allosteric modulation of long-form PDE4 enzymes, a novel disease modifying treatment for Autosomal Dominant Polycystic Kidney Disease” at 2.30pm GMT. At Mironid, we are dedicated to revolutionising […]
Our CEO Neil Wilkie will be in Vienna next week at the annual BioEurope conference to hear about the latest developments in the biopharma industry and connect with partners and peers across the space. At Mironid, we are committed to transforming the treatment landscape for patients with ADPKD and other rare diseases, and we look […]
Last week, David J P Henderson, our Head of Biology, represented Mironid at Kidney Research UK’s Driving Discoveries Conference in Bristol, where he provided an update on our LoAc molecule and its potential as a treatment option for ADPKD. The conference provided an excellent platform to engage with leading experts in the kidney disease community, […]
Read more de Kidney Research UK with David J P Henderson, Head of Biology
Our Chief Executive Officer Neil Wilkie will be in Bruges, Belgium, from 12-14 May at Bio€quity Europe, an opportunity to meet with potential investors to discuss the current issues and trends facing the biotech industry and how to rise above the noise to attract the right investors and partnerships. If you would like to meet […]
Q: As CSO of Mironid, what drives your passion for scientific innovation, and how do you keep your team motivated through challenges? I’ve been a scientist for nearly 30 years, and I feel incredibly fortunate to be in a career where you learn something new every day. At Mironid, I work alongside a talented and […]
Read more de Q&A with Adele Rowley, Chief Scientific Officer
Our CEO Neil Wilkie, CMO Catherine (Cass) Kelleher, MD and CSO Adele Rowley will be attending the J.P. Morgan Healthcare Conference in San Francisco from January 13-16! 2024 was a transformative year for Mironid, with the nomination of our development candidate for ADPKD (Autosomal Dominant Polycystic Kidney Disease), a major step in our mission to […]
Read more de Mironid Attendind J.P. Morgan Healthcare Conference
Q: What have been Mironid’s key achievements this year? A: Our key achievement has been the nomination of our development candidate for ADPKD (Autosomal Dominant Polycystic Kidney Disease). We are now working incredibly hard to progress this candidate through formal pre-clinical toxicology studies and safety pharmacology with a view to moving into the clinic in […]
Read more de 2024 End of Year Update: Q&A with CEO Neil Wilkie